Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

MTSR

Metsera Inc

Sep 12 • 04:00PM ET

35.67

-1.58 -4.24 %

Healthcare • Biotechnology • USA • NASD

Held by: IWM VTI VB XBI VXF VBR VBK IWO SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	55.68%	Shs Outstand	104.89M	Perf Week	-0.56%
Market Cap	3.75B	Forward P/E	-	EPS next Y	-3.55	Insider Trans	-0.00%	Shs Float	46.56M	Perf Month	15.55%
Enterprise Value	3.22B	PEG	-	EPS next Q	-0.72	Inst Own	41.14%	Short Float	19.58%	Perf Quarter	3.15%
Income	-	P/S	-	EPS this Y	78.77%	Inst Trans	3.55%	Short Ratio	7.52	Perf Half Y	47.03%
Sales	-	P/B	8.33	EPS next Y	-15.28%	ROA	-	Short Interest	9.11M	Perf YTD	34.60%
Book/sh	4.28	P/C	7.06	EPS next 5Y	32.96%	ROE	-	52W High	47.40 -24.75%	Perf Year	-
Cash/sh	5.05	P/FCF	-	EPS past 3/5Y	-1497.55% -	ROIC	-	52W Low	12.30 190.00%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.19% 6.70%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.26	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.77	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.26	EPS Q/Q	-239.61%	SMA20	3.46%	Beta	-	Target Price	63.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	0.83%	Rel Volume	1.33	Prev Close	37.25
Employees	81	LT Debt/Eq	0.00	Earnings	Jul 28 AMC	SMA200	22.16%	Avg Volume	1.21M	Price	35.67
IPO	Jan 31, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.29% -	Trades		Volume	1,610,505	Change	-4.24%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-25	Initiated	Leerink Partners	Outperform	$77
Jun-20-25	Initiated	Wells Fargo	Overweight	$65
Feb-25-25	Initiated	Guggenheim	Buy	$56
Feb-25-25	Initiated	Evercore ISI	Outperform
Feb-25-25	Initiated	BofA Securities	Buy	$38

Sep-11-25 11:14AM	Metsera, Inc. (MTSR)'s MET-233i Shows 8% Weight Loss in Phase 1 (Insider Monkey)
07:00AM	Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting (GlobeNewswire)
Sep-10-25 12:59AM	Bank of America Securities Raises PT on Metsera (MTSR), Keeps a Buy (Insider Monkey)
Aug-27-25 04:01PM	Metsera to Present at Upcoming September Investor Conferences (GlobeNewswire) +5.51%
Aug-20-25 12:14AM	Metsera's (MTSR) Amylin Agonist Data Leads to Price Target Increase (Insider Monkey)
04:01PM	Loading…
Jul-28-25 04:01PM	Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress (GlobeNewswire) -5.73%
08:50AM	Recent Price Trend in Metsera Inc. (MTSR) is Your Friend, Here's Why (Zacks)
Jul-14-25 07:52AM	Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association (Insider Monkey) +8.12%
Jul-10-25 09:55AM	Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? (Zacks)
08:50AM	Metsera Inc. (MTSR) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-24-25 09:55AM	Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? (Zacks)
Jun-11-25 07:56PM	Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results (Insider Monkey) -5.81%
Jun-10-25 07:00AM	Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) +15.50%
Jun-09-25 04:08PM	Obesity Newcomer Metsera Enters The Ring With A Punch And A Big Stock Jump (Investor's Business Daily) +10.55%
09:48AM	Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch (Investor's Business Daily)
08:06AM	Loading…
08:06AM	Metsera shares climb on early data for amylin-targeting obesity shot (BioPharma Dive)
07:00AM	Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i (GlobeNewswire)
Jun-05-25 07:30AM	Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association (GlobeNewswire)
May-12-25 07:00AM	Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress (GlobeNewswire) +10.52%
May-08-25 04:01PM	Metsera to Present at Bank of America 2025 Global Healthcare Conference (GlobeNewswire) +7.00%
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Mar-26-25 07:00AM	Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress (GlobeNewswire)
Mar-15-25 04:42PM	Metsera, Inc. (MTSR): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-06-25 10:13AM	Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Mar-03-25 02:50PM	Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey) +15.01%
Mar-01-25 05:02AM	Q4 2024 Amneal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 07:00AM	Metsera to Present at TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
Feb-25-25 02:04PM	Wall Street bullish on Metsera following January IPO on obesity drug pipeline (Investing.com) -8.32%
Feb-19-25 02:50PM	Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently (Insider Monkey)
Feb-05-25 04:01PM	Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
08:13PM	Loading…
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
06:53PM	Metsera Announces Pricing of Initial Public Offering (GlobeNewswire)
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FMR LLC	See Remark 1	Sep 02 '25	Sale	36.00	268	9,648	0	Sep 04 02:58 PM
Burow Kristina	Director	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:15 PM
BERNS PAUL L	Director	Feb 03 '25	Buy	18.00	789,998	14,219,964	8,313,680	Feb 03 07:04 PM
ARCH Venture Partners XII, LLC	10% Owner	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:01 PM

Open in Screener

BEAM

Beam Therapeutics Inc

Sep 12 • 04:00PM ET

20.60

-0.95 -4.41 %

Healthcare • Biotechnology • USA • NASD

BEAM Beam Therapeutics Inc daily Stock Chart

Peers: CRSP NTLA EDIT ALNY SRPT SGMO BLUE CLLS VYGR ADVM

| Held by: ARKK VTI IWM VB ARKG XBI VBK VXF IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-4.51	Insider Own	9.79%	Shs Outstand	100.76M	Perf Week	-1.34%
Market Cap	2.08B	Forward P/E	-	EPS next Y	-4.43	Insider Trans	-1.27%	Shs Float	91.32M	Perf Month	17.58%
Enterprise Value	1.09B	PEG	-	EPS next Q	-1.03	Inst Own	101.31%	Short Float	27.90%	Perf Quarter	18.12%
Income	-398.58M	P/S	34.58	EPS this Y	5.99%	Inst Trans	-7.34%	Short Ratio	10.11	Perf Half Y	-17.80%
Sales	60.27M	P/B	1.98	EPS next Y	-2.90%	ROA	-30.05%	Short Interest	25.48M	Perf YTD	-16.94%
Book/sh	10.39	P/C	1.81	EPS next 5Y	-0.47%	ROE	-41.94%	52W High	35.25 -41.56%	Perf Year	-12.90%
Cash/sh	11.37	P/FCF	-	EPS past 3/5Y	7.43% -20.88%	ROIC	-33.53%	52W Low	13.52 52.31%	Perf 3Y	-63.09%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	7.00% 412.30%	Gross Margin	63.53%	Volatility	6.45% 6.36%	Perf 5Y	-5.63%
Dividend TTM	-	EV/Sales	18.06	EPS Y/Y TTM	-155.64%	Oper. Margin	-739.94%	ATR (14)	1.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.75	Sales Y/Y TTM	-82.90%	Profit Margin	-661.31%	RSI (14)	60.10	Recom	1.31
Dividend Gr. 3/5Y	- -	Current Ratio	6.75	EPS Q/Q	9.34%	SMA20	14.46%	Beta	2.19	Target Price	45.07
Payout	-	Debt/Eq	0.15	Sales Q/Q	-28.08%	SMA50	8.00%	Rel Volume	0.97	Prev Close	21.55
Employees	483	LT Debt/Eq	0.14	Earnings	Aug 05 BMO	SMA200	-5.34%	Avg Volume	2.52M	Price	20.60
IPO	Feb 06, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.12% -33.69%	Trades		Volume	2,439,709	Change	-4.41%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy	$42
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$40
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$27 → $39
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130
Oct-19-21	Initiated	SVB Leerink	Outperform	$117
Sep-24-21	Resumed	Stifel	Buy	$85 → $120

Show Previous Ratings

Sep-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? (Zacks)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
Aug-28-25 08:48AM	CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now? (Zacks)
Aug-25-25 07:00AM	Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences (GlobeNewswire)
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
12:13AM	Loading…
Aug-20-25 12:13AM	JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating (Insider Monkey)
Aug-14-25 07:00AM	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease (GlobeNewswire)
Aug-12-25 11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)
Aug-06-25 11:51AM	BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark (Zacks)
Aug-05-25 08:15AM	Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Jul-30-25 10:00AM	Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-29-25 10:00AM	Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-16-25 09:38AM	Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company (Insider Monkey)
10:45AM	Loading…
Jul-09-25 10:45AM	Innovation ETF (ARKK) Hits New 52-Week High (Zacks) +5.71%
Jul-06-25 04:15AM	H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT (Insider Monkey)
Jul-03-25 09:18AM	Beam Therapeutics' BEAM-101 Shows Promising Results in Sickle Cell Disease Trial (Insider Monkey)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
Jun-19-25 07:22AM	Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? (Zacks)
Jun-18-25 09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily)
Jun-13-25 07:00AM	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-05-25 11:30AM	Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)
Jun-03-25 07:00AM	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease (GlobeNewswire)
May-29-25 11:54PM	FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)' AATD Gene Therapy (Insider Monkey)
04:01PM	Loading…
04:01PM	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-14-25 09:30AM	Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
May-13-25 07:00AM	Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-12-25 04:01PM	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
May-09-25 01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks)
12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
12:25PM	Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
08:55AM	NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up (Zacks)
08:06AM	Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut (Zacks)
May-08-25 12:38PM	Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains (Zacks) +6.32%
12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks)
12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
10:58AM	Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:43AM	Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
10:40AM	Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
May-07-25 08:59AM	BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates (Zacks)
May-06-25 05:05PM	Why Beam Therapeutics Stock Tanked on Tuesday (Motley Fool) -19.32%
01:37PM	Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down (Zacks)
11:07AM	Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised (Zacks)
09:17AM	RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates (Zacks)
08:20AM	Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-05-25 04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-02-25 01:18PM	FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls (Zacks)
12:21PM	Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings (Zacks)
11:10AM	Alkermes' Q1 Earnings and Revenues Fall Short of Estimates (Zacks)
07:53AM	Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates (Zacks)
May-01-25 10:40AM	Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
09:48AM	Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
07:57AM	UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales (Zacks)
Apr-30-25 12:17PM	Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y (Zacks)
09:07AM	Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
Apr-25-25 09:25AM	Beam Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +7.29%
Apr-10-25 09:49AM	Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? (Zacks) -10.63%
Apr-07-25 10:06AM	Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease (Benzinga)
Apr-05-25 07:00AM	Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress (GlobeNewswire)
Apr-01-25 12:42PM	Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? (Insider Monkey) -9.70%
11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-31-25 11:05AM	Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street (The Wall Street Journal) -12.07%
09:03AM	The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics (Zacks)
Mar-30-25 11:35AM	Street Calls of the Week (Investing.com)
Mar-28-25 09:39AM	Promising Genomics & Synthetic Biology Stocks to Consider in 2025 (Zacks)
09:26AM	BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance (Zacks)
Mar-27-25 04:01PM	Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration (GlobeNewswire)
11:30AM	Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-21-25 01:13PM	Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy (SeekingAlpha)
Mar-19-25 10:27AM	CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
Mar-16-25 10:58AM	Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years? (Insider Monkey)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-10-25 09:24AM	Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now? (Insider Monkey) -9.80%
08:25AM	Beam base editing therapy gets proof of concept in rare lung disease (BioPharma Dive)
06:01AM	Beam Therapeutics Announces Pricing of Underwritten Offering (GlobeNewswire)
06:00AM	Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation (GlobeNewswire)
Mar-04-25 09:00PM	Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14% (Benzinga) +5.34%
Feb-25-25 08:15AM	Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts (GlobeNewswire)
Feb-24-25 10:07AM	Cathie Wood buys $11 million of under-the-radar AI stock (TheStreet)
07:00AM	Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences (GlobeNewswire)
Feb-23-25 03:05PM	Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-13-25 09:55AM	Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High? (Zacks)
Feb-10-25 09:40AM	Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-30-25 07:00AM	Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference (GlobeNewswire) +5.29%
Jan-28-25 09:55AM	Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet (Zacks)
Jan-23-25 07:00AM	Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily) -8.77%
10:29AM	Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now? (Zacks)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FMR LLC	See Remark 1	Jul 30 '25	Sale	20.50	48,374	991,667	2,073,665	Aug 01 09:36 AM
Simon Amy	Chief Medical Officer	Jul 03 '25	Sale	20.12	876	17,625	64,864	Jul 03 05:30 PM
Simon Amy	Chief Medical Officer	Jul 01 '25	Sale	16.94	374	6,336	65,740	Jul 03 05:30 PM
Bellon Christine	Chief Legal Officer	Apr 01 '25	Sale	18.35	5,674	104,122	117,294	Apr 03 09:53 PM
Evans John M.	CEO	Apr 01 '25	Sale	18.35	30,663	562,684	986,249	Apr 03 09:52 PM
Ciaramella Giuseppe	President	Apr 01 '25	Sale	18.35	7,434	136,418	190,216	Apr 03 09:51 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Apr 01 '25	Sale	18.35	3,015	55,330	44,512	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 02 '25	Sale	17.73	20,997	372,294	65,742	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 01 '25	Sale	18.35	9,566	175,542	86,739	Apr 03 09:50 PM
AMY SIMON	Officer	Apr 02 '25	Proposed Sale	17.73	20,997	372,294		Apr 02 04:08 PM
AMY SIMON	Officer	Apr 01 '25	Proposed Sale	22.21	30,562	678,782		Mar 31 06:44 PM
JOHN M. EVANS	Officer	Apr 01 '25	Proposed Sale	22.21	64,842	1,440,141		Mar 31 06:43 PM
CHRISTINE BELLON	Officer	Apr 01 '25	Proposed Sale	22.21	18,125	402,556		Mar 31 06:43 PM
GIUSEPPE CIARAMELLA	Officer	Apr 01 '25	Proposed Sale	22.21	23,750	527,488		Mar 31 06:43 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Feb 18 '25	Sale	35.00	6,287	220,045	37,527	Feb 20 04:10 PM
Bellon Christine	Chief Legal Officer	Feb 14 '25	Option Exercise	7.22	10,000	72,200	112,968	Feb 19 04:10 PM
Bellon Christine	Chief Legal Officer	Feb 14 '25	Sale	34.00	10,000	340,000	102,968	Feb 19 04:10 PM
CHRISTINE BELLON	Officer	Feb 14 '25	Proposed Sale	34.00	10,000	340,000		Feb 14 04:06 PM
Evans John M.	CEO	Jan 30 '25	Sale	26.75	30,000	802,484	908,659	Feb 03 04:05 PM
JOHN M EVANS	Officer	Jan 30 '25	Proposed Sale	26.75	30,000	802,482		Jan 30 04:12 PM
Bellon Christine	Chief Legal Officer	Jan 02 '25	Sale	24.68	1,241	30,628	102,968	Jan 06 05:49 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Jan 02 '25	Sale	24.68	1,117	27,568	43,814	Jan 06 05:48 PM
BETHANY J. CAVANAGH	Officer	Dec 31 '24	Proposed Sale	25.27	9,500	240,065		Dec 30 07:29 PM
CHRISTINE BELLON	Officer	Dec 31 '24	Proposed Sale	25.27	4,167	105,300		Dec 30 07:26 PM
Ciaramella Giuseppe	President	Dec 17 '24	Option Exercise	0.67	53,500	35,845	162,650	Dec 19 04:10 PM
Ciaramella Giuseppe	President	Nov 06 '24	Sale	26.36	51,110	1,347,050	109,150	Nov 08 04:10 PM
Ciaramella Giuseppe	President	Oct 14 '24	Option Exercise	2.00	41,754	83,594	211,370	Oct 16 04:44 PM
Ciaramella Giuseppe	President	Oct 14 '24	Sale	26.27	51,110	1,342,752	160,260	Oct 16 04:44 PM
Giuseppe Ciaramella	Officer	Oct 14 '24	Proposed Sale	24.65	102,220	2,519,723		Oct 15 11:37 AM
Burrell Terry-Ann	Officer	Oct 07 '24	Proposed Sale	23.00	185,565	4,267,995		Oct 07 05:00 PM
Bellon Christine	Chief Legal Officer	Oct 01 '24	Sale	23.48	385	9,040	104,209	Oct 02 05:52 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Oct 01 '24	Sale	23.48	289	6,785	44,931	Oct 02 05:51 PM
Evans John M.	CEO	Sep 30 '24	Sale	24.60	60,000	1,476,024	938,659	Oct 02 05:49 PM
JOHN M EVANS	Officer	Sep 30 '24	Proposed Sale	24.60	60,000	1,476,024		Sep 30 04:51 PM

Open in Screener

SANA

Sana Biotechnology Inc

Sep 12 • 04:00PM ET

3.22

-0.18 -5.29 %

Healthcare • Biotechnology • USA • NASD

SANA Sana Biotechnology Inc daily Stock Chart

Peers: VERV PRME NTLA EDIT TSHA CRBU CABA BEAM MGTX PGEN

| Held by: VTI IWM VXF IWN IBB VTWO SCHA VHT SMLF PRFZ

Index	RUT	P/E	-	EPS (ttm)	-1.06	Insider Own	44.13%	Shs Outstand	230.51M	Perf Week	8.78%
Market Cap	833.02M	Forward P/E	-	EPS next Y	-0.66	Insider Trans	0.00%	Shs Float	144.54M	Perf Month	-3.30%
Enterprise Value	841.64M	PEG	-	EPS next Q	-0.18	Inst Own	43.54%	Short Float	20.89%	Perf Quarter	26.77%
Income	-252.18M	P/S	-	EPS this Y	25.49%	Inst Trans	-3.11%	Short Ratio	5.38	Perf Half Y	21.28%
Sales	0.00M	P/B	6.06	EPS next Y	23.97%	ROA	-51.45%	Short Interest	30.20M	Perf YTD	97.55%
Book/sh	0.53	P/C	10.84	EPS next 5Y	12.54%	ROE	-109.12%	52W High	7.30 -55.89%	Perf Year	-35.60%
Cash/sh	0.30	P/FCF	-	EPS past 3/5Y	18.55% -10.60%	ROIC	-129.85%	52W Low	1.26 155.56%	Perf 3Y	-53.06%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.75% 7.59%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	7.58%	Oper. Margin	-	ATR (14)	0.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.47	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.33	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.47	EPS Q/Q	-83.40%	SMA20	0.36%	Beta	1.89	Target Price	8.67
Payout	-	Debt/Eq	0.70	Sales Q/Q	-	SMA50	-13.51%	Rel Volume	0.53	Prev Close	3.40
Employees	194	LT Debt/Eq	0.58	Earnings	Aug 11 AMC	SMA200	18.58%	Avg Volume	5.62M	Price	3.22
IPO	Feb 04, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-94.32% -	Trades		Volume	2,998,072	Change	-5.29%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-03-25	Resumed	Morgan Stanley	Overweight	$12
Mar-18-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$5
Mar-14-25	Initiated	Jefferies	Buy	$7
Jan-08-25	Upgrade	TD Cowen	Hold → Buy
Nov-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-26-24	Initiated	Rodman & Renshaw	Buy	$16
Jan-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Sep-25-23	Initiated	JMP Securities	Mkt Outperform	$9
Sep-05-23	Initiated	Citigroup	Buy	$8
Aug-14-23	Initiated	TD Cowen	Market Perform
May-02-23	Initiated	H.C. Wainwright	Neutral
Mar-01-21	Initiated	Morgan Stanley	Overweight	$40
Mar-01-21	Initiated	JP Morgan	Neutral	$35
Mar-01-21	Initiated	Goldman	Neutral	$40
Mar-01-21	Initiated	BofA Securities	Buy	$45

Show Previous Ratings

Sep-08-25 12:30AM	JMP Securities Keeps Market Outperform Rating on Sana Biotechnology (SANA) (Insider Monkey)
Aug-26-25 04:05PM	Sana Biotechnology to Present at September 2025 Investor Conferences (GlobeNewswire)
Aug-25-25 11:56PM	Citizens JMP Reiterates a Buy Rating on Sana Biotechnology (SANA) With a $5 PT (Insider Monkey) -6.42%
Aug-20-25 04:05PM	Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Aug-12-25 11:43AM	Sana Biotech Bails on Factory in Old AT&T Call Center (IEN) +6.51%
06:11PM	Loading…
Aug-11-25 06:11PM	Sana: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -30.12%
Aug-06-25 11:24PM	Sana Biotechnology Announces Pricing of Public Offering (GlobeNewswire)
04:38PM	Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
07:00AM	Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-04-25 11:35AM	Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes (GlobeNewswire) +8.18%
Aug-01-25 06:47AM	Sana Biotechnology (SANA) Rated 'Market Perform' on Diabetes Program Prospects (Insider Monkey)
Jul-31-25 11:40PM	Citi Remains Bullish on Sana Biotechnology (SANA) (Insider Monkey) -6.88%
Jul-23-25 11:25AM	Citi Maintained a Buy Rating on Sana Biotechnology (SANA) (Insider Monkey) +5.54%
07:11PM	Loading…
Jul-11-25 07:11PM	Sana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan Stanley (Insider Monkey)
Jul-03-25 09:09AM	Sana Reports Promising Diabetes Cell Therapy Data at ADA Meeting (Insider Monkey) +9.25%
Jun-24-25 03:51PM	BofA Remains Bullish on Sana Biotechnology (SANA) (Insider Monkey) +14.23%
Jun-23-25 10:05AM	Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression (GlobeNewswire)
Jun-09-25 04:05PM	Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions (GlobeNewswire)
May-28-25 04:05PM	Sana Biotechnology to Present at June 2025 Investor Conferences (GlobeNewswire) +12.50%
May-12-25 04:05PM	Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference (GlobeNewswire) +9.89% -10.25%
May-08-25 04:42PM	Sana: Q1 Earnings Snapshot (Associated Press Finance) +6.47%
04:05PM	Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
May-06-25 10:12PM	Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development (PR Newswire) -8.56%
Apr-29-25 08:00AM	Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics (PR Newswire)
Apr-24-25 06:00AM	Flagship Pioneering Unveils Etiome to Pioneer Preemptive Healthcare (PR Newswire)
Apr-22-25 05:45AM	Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA (PR Newswire) +8.81%
Apr-21-25 12:56PM	Sana Biotechnology, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights SANA (GlobeNewswire)
Apr-16-25 11:23AM	Is Sana Biotechnology Inc. (NASDAQ:SANA) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -7.06%
12:39PM	Loading…
Apr-10-25 12:39PM	Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights SANA (GlobeNewswire)
Apr-01-25 08:00AM	Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease (PR Newswire) -10.71%
Mar-25-25 08:00AM	Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica, an AI-Powered Drug Discovery Platform (Business Wire) -11.16%
Mar-24-25 11:45PM	Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421 (SeekingAlpha)
Mar-17-25 04:14PM	Sana: Q4 Earnings Snapshot (Associated Press Finance) -5.46% -17.69%
04:05PM	Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Mar-04-25 04:04PM	Is Sana Biotechnology (SANA) Among Jeff Bezos Investments in 2025? (Insider Monkey) +5.35%
Mar-01-25 06:02PM	Why Sana Biotechnology, Inc. (SANA) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-24-25 04:05PM	Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference (GlobeNewswire) -10.07%
Jan-28-25 10:42AM	Sana Biotechnology, Inc. (SANA): A Bull Case Theory (Insider Monkey)
Jan-22-25 07:59AM	Is Sana Biotechnology, Inc. (SANA) the Hottest Smid-Cap Stock So Far In 2025? (Insider Monkey) +19.86%
Jan-08-25 04:05PM	Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +160.61% -14.88%
10:34AM	Sana Biotechnology (SANA), eBay (EBAY) Are Among Todays Big Winners (Insider Monkey)
10:11AM	This Biotech Stock Soared 300% Overnight. Why It Can Go Higher. (Barrons.com)
07:26AM	Sana Biotechnology price target lowered to $7 from $8 at BofA (TipRanks)
07:25AM	This Biotech Stock Just Soared 240%. Why It Can Go Higher. (Barrons.com)
06:31AM	Tenvie raises $200M for brain drug R&D; Sana spikes on single patients results (BioPharma Dive)
Jan-07-25 04:05PM	Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression (GlobeNewswire) -5.71%
Dec-02-24 09:00AM	Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus (GlobeNewswire)
Nov-25-24 04:05PM	Sana Biotechnology to Present at December 2024 Investor Conferences (GlobeNewswire)
Nov-20-24 08:00AM	Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies (PR Newswire) +7.20%
06:30AM	Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer (PR Newswire)
Nov-13-24 09:55AM	Here's Why Sana (SANA) Could be Great Choice for a Bottom Fisher (Zacks) -6.34%
08:00AM	Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio (PR Newswire)
08:00AM	Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner (PR Newswire)
Nov-11-24 09:35AM	Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround (Zacks)
Nov-08-24 09:10AM	Sana: Q3 Earnings Snapshot (Associated Press Finance)
09:00AM	Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Nov-05-24 04:40AM	Sana to lay off staff, deepen autoimmune focus in latest retrenchment (BioPharma Dive) -9.84%
Nov-04-24 04:30PM	Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025 (GlobeNewswire)
Oct-23-24 08:00AM	Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence (PR Newswire)
Oct-16-24 08:58AM	Why Sana Biotechnology, Inc. (SANA) is the Penny Stock with the Biggest Upside Potential According to Analysts (Insider Monkey)
Oct-13-24 04:48PM	Sana Biotechnology, Inc. (SANA): Jeff Bezos Is Buying This Stock Now (Insider Monkey)
Oct-09-24 07:00AM	Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions (PR Newswire)
Oct-03-24 08:00AM	Invaio Sciences Appoints Andr Andonian as Chairman of the Board of Directors (PR Newswire)
Sep-30-24 04:05PM	Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference (GlobeNewswire)
Sep-26-24 06:00AM	Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry (PR Newswire) +13.56%
Aug-29-24 04:05PM	Sana Biotechnology to Present at September 2024 Investor Conferences (GlobeNewswire)
Aug-28-24 06:30AM	Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer (PR Newswire)
Aug-26-24 04:05PM	Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer (GlobeNewswire)
Aug-08-24 05:03PM	Sana: Q2 Earnings Snapshot (Associated Press Finance) +5.36%
04:05PM	Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Aug-06-24 06:30AM	Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner (PR Newswire)
Jul-29-24 07:00AM	GSK and Flagship Pioneering partner to discover novel medicines and vaccines (PR Newswire)
Jul-25-24 08:00AM	Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World (PR Newswire)
Jul-23-24 06:00AM	Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class (PR Newswire)
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire) -7.00%
Jul-10-24 06:00AM	Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations that Transform Human Health and Sustainability (PR Newswire)
06:00AM	Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions (PR Newswire)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire)
May-21-24 09:00AM	Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington's Disease and Other Glial-based Neurodegenerative Conditions (GlobeNewswire)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia) -7.77%
May-10-24 01:35PM	Sana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-09-24 07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire) -20.97%
May-08-24 10:55PM	SANA Stock Earnings: Sana Biotechnology Meets EPS for Q1 2024 (InvestorPlace) -5.48%
05:22PM	Sana: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
May-06-24 04:05PM	Sana Biotechnology to Present at May and June 2024 Investor Conferences (GlobeNewswire)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-19-24 10:00AM	CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) (GlobeNewswire)
08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire)
Mar-11-24 07:00PM	Director Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA) (GuruFocus.com)
Mar-07-24 09:01AM	Baillie Gifford Bolsters Stake in Sana Biotechnology Inc (GuruFocus.com)
Feb-29-24 04:55PM	Sana: Q4 Earnings Snapshot (Associated Press Finance) -5.90% +12.25%
04:05PM	Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates (GlobeNewswire)
03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-28-24 04:05PM	Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference (GlobeNewswire) +7.34%
Feb-13-24 04:05PM	Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP (GlobeNewswire) +15.15%
Feb-12-24 04:05PM	Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-08-24 01:22AM	Sana Biotechnology Announces Pricing of Upsized Public Offering (GlobeNewswire)

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wyrick Susan D.	See Remarks	Mar 07 '25	Option Exercise	0.00	3,250	0	158,231	Mar 10 08:13 PM
Cassidy Bernard J	EVP & General Counsel	Mar 07 '25	Option Exercise	0.00	11,041	0	115,823	Mar 10 08:12 PM
Harr Steve	President & CEO	Mar 07 '25	Option Exercise	0.00	50,000	0	7,889,750	Mar 10 08:12 PM
Wyrick Susan D.	See Remarks	Mar 02 '25	Option Exercise	0.00	1,525	0	155,471	Mar 03 07:28 PM
CHRISTIAN HORDO & KATHARINE HO	Officer	Feb 18 '25	Proposed Sale	3.16	75,000	237,000		Feb 18 04:27 PM
CHRISTIAN HORDO & KATHARINE HO	Officer	Jan 16 '25	Proposed Sale	3.86	75,000	289,500		Jan 16 04:31 PM
FMR LLC	See Remark 1	Jan 08 '25	Sale	6.49	290,912	1,887,320	4,541,511	Jan 10 01:32 PM
Wyrick Susan D.	See Remarks	Jan 02 '25	Option Exercise	0.00	5,000	0	155,512	Jan 03 04:15 PM
CHRISTIAN HORDO & KATHARINE HO	Officer	Dec 16 '24	Proposed Sale	1.89	75,000	141,750		Dec 16 04:33 PM
Hardy Nathan	Former CFO	Nov 26 '24	Proposed Sale	2.50	91,607	229,018		Nov 26 06:20 PM
NATHAN HARDY	Former CFO	Nov 25 '24	Proposed Sale	2.50	25,933	64,960		Nov 25 05:40 PM
NATHAN HARDY	Officer	Oct 21 '24	Proposed Sale	3.95	45,796	180,807		Oct 21 05:19 PM
Mulligan Richard	Director	Sep 24 '24	Sale	4.08	150,000	612,570	2,848,121	Sep 26 04:07 PM
Mulligan Richard	Director	Sep 25 '24	Sale	3.89	150,000	583,170	2,698,121	Sep 26 04:07 PM
RICHARD MULLIGAN	Director	Sep 25 '24	Proposed Sale	4.09	150,000	613,500		Sep 25 04:20 PM
RICHARD MULLIGAN	Director	Sep 24 '24	Proposed Sale	4.09	150,000	613,500		Sep 24 04:28 PM

MTSR

Metsera Inc

BEAM

Beam Therapeutics Inc

SANA

Sana Biotechnology Inc

Upgrade your FINVIZ experience